CANCER IMMUNOTHERAPY WITH VEGFR-3 TARGETED CAR T-CELLS

Details

Ressource 1Download: Mémoire no 3405 M. Kiritsis.pdf (2081.72 [Ko])
State: Public
Version: After imprimatur
Serval ID
serval:BIB_AD0E970E95CE
Type
A Master's thesis.
Publication sub-type
Master (thesis) (master)
Collection
Publications
Institution
Title
CANCER IMMUNOTHERAPY WITH VEGFR-3 TARGETED CAR T-CELLS
Author(s)
KIRITSIS K.
Director(s)
COUKOS G.
Codirector(s)
IRVING M.
Institution details
Université de Lausanne, Faculté de biologie et médecine
Publication state
Accepted
Issued date
2016
Language
english
Number of pages
32
Abstract
Tumorigenesis is the generation and proliferation of cells that have undergone genotypical and phenotypical alterations that
disrupt the physiological balance between proliferation and death. In humans, evidence shows that tumorigenesis is a multistep process, where each step is a genetic mutational event that contributes to the cell tumorigenictraits.1Douglas Hanahan highlighted in his highly cited “Hallmarks of Cancer” (2000) that
mutated cells display six potentials that are shared by most if not all cancer types (Fig 1). Those characteristics, which dictate cancer expansion, include self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death (known as apoptosis), limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis.

Keywords
Cancer, Immunotherapy, CAR T-cells, Vasculature. VEGFR3
Create date
05/09/2017 13:49
Last modification date
20/08/2019 15:17
Usage data